54 filings
Page 2 of 3
8-K
g7lbt vfofvf
26 Oct 22
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:10pm
8-K
i9l012dgwv0 de
4 Oct 22
Entry into a Material Definitive Agreement
8:02am
8-K
0bdw9 xpzjokhv5
15 Aug 22
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
4:09pm
8-K
pxvhl2 b6bwhcx56bs
10 Aug 22
Regulation FD Disclosure
4:06pm
8-K
oe4ya016c 000jhpp0y
8 Aug 22
Inhibrx Reports Second Quarter 2022 Financial Results
4:19pm
8-K
obzn8keb0ucay49
30 Jun 22
Regulation FD Disclosure
9:01am
8-K
od6rjptiq42tv1x6fj
16 Jun 22
Entry into a Material Definitive Agreement
4:05pm
8-K
56xbjgee 5baad25z
25 May 22
Submission of Matters to a Vote of Security Holders
5:23pm
8-K
1vs5yp dplpqd0uk
16 May 22
Regulation FD Disclosure
9:03am
8-K
nhysuu9f ta077juf
9 May 22
Inhibrx Reports First Quarter 2022 Financial Results
4:10pm
8-K
70f58xhthlb6th
25 Apr 22
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
9:04am
8-K
g2loifdap
5 Apr 22
Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting
4:32pm
8-K
e08ksldp7 0g79vvs3
4 Apr 22
Regulation FD Disclosure
4:06pm
8-K
m35osng0wydls5vqw
3 Mar 22
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:22am
8-K
w4img3asikpwpb2ovh7
28 Feb 22
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results
4:12pm
8-K
xy0cr4 wxu3o1r
22 Feb 22
Inhibrx Announces Amended Loan Agreement with Oxford
9:11am
8-K
js2u6ijk
25 Jan 22
Departure of Directors or Certain Officers
12:00am
8-K
rqfq12l
4 Jan 22
Regulation FD Disclosure
4:41pm
8-K
yos48s78yw
1 Dec 21
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
4:07pm
8-K
lhljpm17a1pzova
9 Nov 21
Inhibrx Reports Third Quarter 2021 Financial Results
4:37pm